R
ReVision Optics
Innovative near vision inlay solutions for presbyopia, reducing or eliminating the need for reading glasses
About ReVision Optics
ReVision Optics, based in Southern California, specializes in providing advanced solutions for individuals suffering from presbyopia, a condition that affects near vision typically in people aged 41 to 65. The company's flagship product, the Raindrop Near Vision Inlay, is a small, transparent disk designed to improve near vision by being implanted in the non-dominant eye. This innovative inlay aims to reduce or eliminate the need for reading glasses, offering a convenient and effective alternative for those struggling with near vision loss.
ReVision Optics operates in the medical device market, focusing on ophthalmology and vision correction. The company primarily serves patients who are presbyopic and do not require correction for clear distance vision but need near vision correction. The business model revolves around the sale of the Near Vision Inlay, which is FDA-approved and must be prescribed and implanted by a qualified physician. Revenue is generated through the direct sale of these inlays to medical professionals and clinics.
The company emphasizes safety and efficacy, providing extensive information on potential risks, indications, and precautions associated with the Near Vision Inlay. By addressing a common age-related vision issue, ReVision Optics positions itself as a leader in the niche market of presbyopia treatment.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 1996
- Headquarters
- Lake Forest, United States
- Open positions
- None listed
- Dealroom signal
- 55.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Personal Health, Diabetes, Risk Management, Biotechnology, Surgery, Optical Technology, Biotech and Pharma, Hard Tech, DT and LS, science-based, Eyewear
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Nov 2016 | $32M | $128M | Johnson & Johnson Development Corporation | — |
| SERIES EOther financing | Apr 2013 | $15M | $60M | Johnson & Johnson Development Corporation · Domain Associates · ProQuest Investments · Canaan | — |
Growth signals
Latest recorded traffic for ReVision Optics is 70 monthly website visits, down 22.2% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later6 investors entered at this stage
Canaan
InterWest Partners
Domain Associates- PIProQuest Investments
Johnson & Johnson Development Corporation
RMI Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about ReVision Optics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ReVision Optics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






